CryoPort AI Stock Analysis
Want to see CYRX full AI Analyst Report?
CryoPort (CYRX) AI Stock Analysis
CryoPort
(NASDAQ:CYRX)
The score is held back primarily by weak financial quality despite strong top-line growth—losses persist and free cash flow remains materially negative. Technical signals are also bearish (negative MACD, RSI ~40, and price below key short-term moving averages). Offsetting these factors, the latest earnings call was constructive with raised revenue guidance and a second straight quarter of positive adjusted EBITDA, but execution risks (application delays, conservative Q4 outlook, and limited China growth) remain.
CryoPort Key Performance Indicators (KPIs)
Revenue by GeographyBreaks down sales across regions to reveal geographic strengths and concentration risks, indicating where the company is expanding, which markets drive growth, and where regulatory or economic changes could affect future revenue.
Americas is the clear growth engine—its steady recovery and the Q1 beat tie directly to commercial cell‑and‑gene and clinical‑trial momentum—while APAC and EMEA have materially weakened, with APAC collapsing after a lumpy spike and EMEA trending down (including a discrete negative quarter), creating geographic concentration risk. Management’s cautious, modest guide lift and planned Paris/Santa Ana capacity ramps imply they expect Americas and commercial conversions to carry 2026, but failure to stabilize APAC/EMEA could meaningfully cap upside until multi‑quarter facility and IntegraCell ramps complete.
CryoPort (CYRX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $999.81M
- Dividend Yield
- ―
- Average Volume (3M)
- 808.55K
- Price to Earnings (P/E)
- -22.1
- Beta (1Y)
- 1.18
- Revenue Growth
- 1.15%
- EPS Growth
- 21.02%
- Country
- US
- Employees
- 688
- Sector
- Industrials
- Sector Strength
- 63
- Industry
- Integrated Freight & Logistics
CryoPort Business Overview & Revenue Model
Company Description
Cryoport, Inc. operates as a specialized service provider within the life sciences sector, delivering global temperature-controlled supply chain solutions across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Central to t...
How the Company Makes Money
CryoPort primarily makes money by selling logistics services and related solutions that enable the compliant, temperature-controlled movement of sensitive life-science materials. Key revenue streams include: (1) Cryogenic and cold-chain logistics ser...
CryoPort Earnings Call Summary
The call was strongly positive. Cryoport reported 14% revenue growth, 18% growth in Life Sciences Services, 20% growth in commercial cell and gene therapy activity, a record clinical trial pipeline, positive adjusted EBITDA for the second consecutive quarter, and increased full-year revenue guidance. Management also highlighted expanding bioservice capabilities, continued MVE demand, and a favorable cell and gene therapy market outlook. The main challenges were delayed applications, limited China growth, cyclical animal health demand, selective margin impact from facility expansions, and conservative fourth-quarter guidance.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Cryoport raised full-year 2026 revenue guidance to $197 million to $199 million, representing 12% growth year-over-year, with “upside potential for that as well”; the implied Q4 revenue range was $50 million to $52 million, with guidance described as “prudent,” “conservative,” and reflecting a “minimum,” and new approvals are “really not baked into the guidance.” For the remainder of 2026, the company expects “5 possible BLA/MAA application filings,” “2 potential new therapy approvals,” and “1 additional supplemental approval for geographic expansion,” with 1 approval scheduled in November and 1 in December, while 4 applications were pushed into 2027. MVE is expected to deliver “solid mid-single-digit growth on a continued basis,” China represents “about 3% to 4%” of total revenue with “no significant growth,” and biostorage and bioservices are expected to continue as a “double digit grower.” Long-term goals are 55% gross margin and 30% adjusted EBITDA, with “further EBITDA margin expansion in 2027 and beyond,” while cell and gene therapies are expected to grow at a “6 year 30-34% CAGR” from $10.2 billion in 2025 to roughly $60 billion in 2030.
CryoPort Financial Statement Overview
Summary
Revenue growth is very strong (TTM +321.1%) and gross margin is steady (~47%), but profitability remains negative (EBIT and net income losses; ~-22% net margin). The balance sheet looks reasonably levered (debt-to-equity ~0.48) yet returns are negative due to losses. Cash flow is a key risk: operating cash flow is positive (~$11.0M) but free cash flow remains meaningfully negative (~-$18.3M) and cash conversion has been inconsistent.
Income Statement
44NeutralBalance Sheet
63PositiveCash Flow
38Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 192.44M | 176.18M | 233.25M | 237.28M | 222.61M | 222.61M |
| Gross Profit | 90.28M | 83.05M | 99.33M | 103.87M | 96.58M | 96.58M |
| EBITDA | -7.21M | -2.10M | -63.09M | -1.47M | -246.39M | -248.91M |
| Net Income | -40.18M | 78.30M | -99.59M | -37.33M | -275.53M | -275.53M |
Balance Sheet | ||||||
| Total Assets | 750.95M | 764.99M | 703.49M | 957.74M | 1.04B | 1.11B |
| Cash, Cash Equivalents and Short-Term Investments | 393.08M | 411.21M | 261.75M | 456.75M | 523.32M | 628.80M |
| Total Debt | 231.51M | 230.72M | 250.70M | 416.00M | 435.91M | 427.06M |
| Total Liabilities | 267.43M | 262.35M | 301.59M | 468.72M | 482.91M | 471.14M |
| Stockholders Equity | 483.51M | 502.64M | 401.90M | 489.02M | 555.84M | 641.83M |
Cash Flow | ||||||
| Free Cash Flow | -18.28M | -28.09M | -33.58M | -45.66M | -26.05M | -16.88M |
| Operating Cash Flow | 11.00M | -8.58M | -16.32M | -757.00K | -1.85M | 8.13M |
| Investing Cash Flow | 17.13M | 250.32M | 176.81M | 36.05M | -59.68M | -469.25M |
| Financing Cash Flow | -1.20M | -21.07M | -161.53M | -23.80M | -39.17M | 564.34M |
CryoPort Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYRX, the sentiment is Positive. The current price of 19.74 is above the 20-day moving average (MA) of 18.53, above the 50-day MA of 17.60, and above the 200-day MA of 13.81, indicating a bullish trend. The MACD of 0.75 indicates Negative momentum. The RSI at 59.76 is Neutral, neither overbought nor oversold. The STOCH value of 68.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CYRX.
CryoPort Risk Analysis
CryoPort disclosed 33 risk factors in its most recent earnings report. CryoPort reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskCryoPort Peers Comparison
Overall Rating
EXPD78Outperform
FDX70Outperform
UPS66Neutral
CHRW62Neutral
GXO54Neutral
CYRX51Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | $24.63B | 24.15 | 45.78% | 0.83% | 18.64% | 28.14% | |
| 70Outperform | $74.93B | 19.52 | 12.56% | 1.49% | 3.09% | 14.94% | |
| 66Neutral | $93.93B | 21.23 | 28.51% | 5.95% | 2.29% | -19.62% | |
| Sector * | 63Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
| 62Neutral | $15.99B | 24.36 | 39.59% | 1.83% | 10.38% | 12.97% | |
| 54Neutral | $6.21B | 46.56 | 4.56% | ― | 7.08% | 54.11% | |
| 51Neutral | $1.00B | -22.11 | -8.15% | ― | 1.15% | 21.02% |
* Industrials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CYRX | CryoPort Inc | 19.74 | 11.37 | 135.84% | |
| CHRW | Ch Robinson Worldwide | 137.95 | -8.39 | -5.73% | |
| EXPD | Expeditors International Of Washington | 190.77 | 53.90 | 39.38% | |
| FDX | FedEx Corporation | 319.94 | 111.61 | 53.58% | |
| UPS | United Parcel Service | 110.31 | 24.83 | 29.04% | |
| GXO | Gxo Logistics Inc | 54.95 | 8.74 | 18.91% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
